Servier Trial on Diabetes Drug Can Resume After Ruling, AFP Says

The trial of Les Laboratoires Servier and its founder over allegations they hid risks linked to a diabetes drug can resume after an appeals court today refused to ask France’s constitutional court to review their challenge to the case, Agence France-Presse said today, citing lawyers involved in the matter.

A hearing has been set for December to reschedule the trial, which was suspended in May, AFP said.

To contact the reporter on this story: Heather Smith in Paris at hsmith26@bloomberg.net

To contact the editor responsible for this story: Christopher Scinta at cscinta@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.